In its latest quarterly filing, Decoy Therapeutics highlights integration and development progress following its late-2025 merger with Salarius Pharmaceuticals, alongside steps taken to satisfy Nasdaq's minimum bid price rule through a reverse stock split. The company maintains solid liquidity supported by a 1.84 current ratio and zero debt, enabling continued R&D investment. Its clinical-stage pipeline focuses on innovative cancer and viral disease therapeutics, enhanced by promising in silico antiviral data and global access engagements. Notable challenges include typical biotech regulatory risks and the residual risk associated with Nasdaq monitoring conditions.